A TROP2-targeting ADC synergizes with oxidative phosphorylation inhibitor to enhance apoptosis in ESCC by suppressing the PI3K-AKT-mTOR signaling pathway. Here, TACSTD2 is linked to esophageal squamous cell carcinoma.